Cargando…

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study

OBJECTIVE: To evaluate extended dosing intervals (EDIs) with lanreotide Autogel 120 mg in patients with acromegaly previously biochemically controlled with octreotide LAR 10 or 20 mg. DESIGN AND METHODS: Patients with acromegaly had received octreotide LAR 10 or 20 mg/4 weeks for ≥6 months and had n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neggers, Sebastian JCMM, Pronin, Vyacheslav, Balcere, Inga, Lee, Moon-Kyu, Rozhinskaya, Liudmila, Bronstein, Marcello D, Gadelha, Mônica R, Maisonobe, Pascal, Sert, Caroline, van der Lely, Aart Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544680/ https://www.ncbi.nlm.nih.gov/pubmed/26047625 http://dx.doi.org/10.1530/EJE-15-0215

Ejemplares similares

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
por: Tutuncu, Yasemin, et al.
Publicado: (2011)

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
por: Bernabéu, Ignacio, et al.
Publicado: (2020)

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
por: Caron, Philippe J., et al.
Publicado: (2014)

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel(®)
por: Roelfsema, Ferdinand, et al.
Publicado: (2008)

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
por: Petersenn, Stephan, et al.
Publicado: (2019)

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
por: Chanson, Philippe, et al.
Publicado: (2008)

Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective
por: Bevan, J S, et al.
Publicado: (2008)

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study
por: Caron, Philippe J., et al.
Publicado: (2015)

Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report
por: Aerts, Maridi, et al.
Publicado: (2017)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery
por: Alvarez-Escola, Cristina, et al.
Publicado: (2015)

Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial
por: Lucas, T, et al.
Publicado: (2006)

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
por: Ryan, P, et al.
Publicado: (2019)

Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2019)

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)
por: Adelman, Daphne, et al.
Publicado: (2020)

The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma
por: Lybaert, Willem
Publicado: (2014)

Lanreotide Autogel in the Treatment of Persistent Diarrhea following a Total Colectomy
por: Schoeters, Patrick, et al.
Publicado: (2015)

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2019)

Correction to: Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2020)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Pregnancy and acromegaly
por: Muhammad, Ammar, et al.
Publicado: (2016)

Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)
por: An, Zhenmei, et al.
Publicado: (2020)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-month phase of Lanro-Study
por: Orlewska, Ewa, et al.
Publicado: (2013)

Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel
por: Zafra, Gema Marín, et al.
Publicado: (2016)

Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism
por: Corda, Heike, et al.
Publicado: (2017)

MON-LB47 An International Simulated Use Study (PRESTO) to Evaluate Nurse Preferences Between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe
por: Adelman, Daphne T, et al.
Publicado: (2020)

Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors
por: Dromain, Clarisse, et al.
Publicado: (2021)

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
por: Mercado, Moises, et al.
Publicado: (2007)

Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report
por: Lybaert, Willem, et al.
Publicado: (2014)

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
por: Ito, Tetsuhide, et al.
Publicado: (2017)

Approach to the Patient With Treatment-resistant Acromegaly
por: Coopmans, Eva C, et al.
Publicado: (2022)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
por: Caplin, Martyn E., et al.
Publicado: (2020)

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria
por: Rinke, Anja, et al.
Publicado: (2021)

LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors – results of interim analysis
por: Orlewska, Ewa, et al.
Publicado: (2014)

A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide
por: Yamaoka, Keiko, et al.
Publicado: (2021)

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study
por: Martín-Richard, Marta, et al.
Publicado: (2013)

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
por: Bronstein, Marcello D., et al.
Publicado: (2016)

Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea
por: Chin, Sang Ouk, et al.
Publicado: (2015)

Economics of Acromegaly Treatment in Brazil: A Budget Impact Analysis of Pituitary Surgery Compared with Long-Term Octreotide LAR
por: Porto, Lara Benigno, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o44fcvghh1uv009r7pqg0ensco